ArticleNature cancer2023
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
15.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates.Frontiers in immunology · 2026Pooled it
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive/HER2-negative early breast cancer.Breast cancer research : BCR · 2026Article
- Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women.Nature aging · 2026Article
- Subtype-specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers.Molecular oncology · 2026Article
- Spatial analyses implicate high stromal tumour-infiltrating CD8Nature communications · 2026Article
- Pulsed photobiomodulation reprograms the tumor immune microenvironment to restore local T cell-mediated antitumor immunity.iScience · 2026Article
- CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer.Oncogene · 2026Article
- Explainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer.Nature communications · 2026Article
- LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.Cancer research · 2026Article
- Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer.bioRxiv : the preprint server for biology · 2026Article
- E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.Nature communications · 2026Article
- Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial.Cancer immunology research · 2026Article
- A highly resolved integrated single-cell atlas of human breast cancers.NAR genomics and bioinformatics · 2026Article
- Development and validation of a ferroptosis-related gene signature for prognostic prediction and therapeutic target identification in invasive lobular carcinoma.Translational cancer research · 2026Article
- Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.The Journal of clinical investigation · 2026Article
- The Immunoregulatory Roles of ERα in Breast Cancer: Mechanisms, Crosstalk, and Therapeutic Insights.Journal of cancer prevention · 2026Review
- Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer.The Journal of clinical investigation · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 3 institutions in 1 country.
Sayali OnkarDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jian CuiDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jian ZouDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
Carly CardelloDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Anthony R CilloDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-3213-3129
Mostofa Rafid UddinComputational Biology Department, Carnegie Mellon University, Pittsburgh, PA, USA.
April SaganDepartment of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-6467-3958
Marion JoyUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Hatice U OsmanbeyogluDepartment of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
Katherine L Pogue-GeileNSABP Foundation, Pittsburgh, PA, USA.
Priscilla F McAuliffeSection of Breast Surgery, Division of Surgical Oncology, Department of Surgery, University of Pittsburgh College of Medicine, Magee Women's Hospital of UPMC, Pittsburgh, PA, USA.
Peter C LucasUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
George C TsengDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
Adrian V LeeWomen's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Tullia C BrunoDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-6433-0207
Steffi OesterreichWomen's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA. oesterreichs@upmc.edu.ORCID http://orcid.org/0000-0002-2537-6923
Dario A A VignaliDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dvignali@pitt.edu.ORCID http://orcid.org/0000-0002-2771-5992
University of Pittsburgh · USNSABP Foundation · USUPMC Hillman Cancer Center · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MSynergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2015 to 2026
$30.8MTraining in Cellular & Molecular Mechanisms of Tumor RejectionT32CA082084 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder, Dario AA Vignali · 1999 to 2026
$9.2MRegulatory T cells and the tumor microenvironmentR35CA263850 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2021 to 2026
$5.4MDeveloping and credentialing murine models of ILCR01CA252378 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Adrian V Lee, Steffi Oesterreich · 2021 to 2026
$3.0MComputational methods for delineating cell context-specific regulatory programsR35GM146989 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Hatice Ulku Osmanbeyoglu · 2022 to 2026
$1.9MInterleukin-35 and the tumor microenvironmentR01CA203689 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VIGNALI, DARIO AA · 2016 to 2020
$1.9MNCI NIH HHS P30 CA047904NCI NIH HHS R01 CA203689NCI NIH HHS R01 CA252378NCI NIH HHS R35 CA263850NCI NIH HHS T32 CA082084NIAID NIH HHS P01 AI108545NIGMS NIH HHS R35 GM146989
Abstract
T cell-centric immunotherapies have shown modest clinical benefit thus far for estrogen receptor-positive (ER
Indexed as
Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularDisease-Free SurvivalFemaleHumansTreatment OutcomeTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.